In settling with the FDA, Osiris has negotiated to take their micronized product Ovation off the market next year. They will replace it with a non-micronized product, OvationOS. You don't want to mess with the FDA or Big Pharma.
I have two private healthcare investmenst right now. One has been relegated to getting approval in the EU because of the FDA's problems with another orhopedic company which means the time and costs both have increased by multiples. Both companies' ultimate values will only be realized through buyouts if ever. With those on my plate, I don' t need any more buyout dependent investments. I've got it on my radar now though just in case they do a public secondary or a PIPE.